Companies / BOC Sciences / guselkumab
BOC Sciences

guselkumab | BOC Sciences

guselkumab is a selectively blocking agent for interleukin-23 (IL-23), a cytokine involved in plaque psoriasis. guselkumab was approved by FDA as an anti-inflammatory drug for the treatment of moderate to severe plaque psoriasis.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.